Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 9 Fallopian Tube Neoplasms 8 Neoplasms 6 Prostatic Neoplasms 5 Carcinoma, Ovarian Epithelial 5 Recurrence 3 Pancreatic Neoplasms 3 Breast Neoplasms 3 Urinary Bladder Neoplasms 2 Metastatic Castration Resistant Prostate Cancer 2 Colorectal Neoplasms 2 Carcinoma, Transitional Cell 2 Uterine Cervical Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Solid Tumor 1 Sarcoma 1 Primary Myelofibrosis 1 Pathologic Complete Response 1 Neoplasm Metastasis 1 Myeloproliferative Disorders 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Lung Neoplasms 1

Interventions

Paclitaxel 2 vorolanib 1 spartalizumab 1 rucaparib 1 relatlimab 1 linrodostat 1 camrelizumab 1 Nivolumab 1 Ipilimumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Advanced Gastric Cancer × rucaparib × Clear all

NCT02935634 2023-06-09

FRACTION-GC

Bristol-Myers Squibb

Phase 2 Completed

190 enrolled 25 charts

Gastrointestinal

Advanced Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡